Stephens downgraded Akoya Biosciences (AKYA) to Equal Weight from Overweight with a price target of $1.80, down from $3.50, given the pending acquisition by Quanterix (QTRX). If the deal is closed as proposed in Q2, it would represent an attractive return on Akoya shares based on current prices, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.